Lanadelumab

Introduction Overview

Generic Name

Lanadelumab

Brand Name

Takhzyro

Dosage Form

Subcutaneous injection. Single-dose prefilled syringe (150 mg/mL, 300 mg/2 mL), Single-dose vial (300 mg/2 mL)

Drug Class

Hereditary angioedema agents

Pharmacokinetics

Absorption:
Lanadelumab, administered subcutaneously, exhibits predictable and efficient absorption into systemic circulation. Following subcutaneous injection, peak plasma concentrations are generally reached within 7 to 14 days, indicative of slow absorption characteristic of monoclonal antibodies. This slow absorption is advantageous for maintaining stable plasma levels, contributing to its biweekly or monthly dosing schedule. Factors such as local blood flow, injection site, and patient physiology may marginally influence absorption rates. Clinical studies indicate that absorption is consistent across adult and pediatric populations aged 2 years and older.

Distribution:
Being a monoclonal antibody, lanadelumab primarily distributes within the vascular and interstitial spaces. It exhibits a volume of distribution typical of large proteins, approximately equivalent to plasma volume, reflecting limited extravascular penetration. The molecule does not cross the blood-brain barrier or placental barriers readily. Binding is highly specific to plasma kallikrein with negligible nonspecific tissue binding. Due to its protein nature, lanadelumab is not expected to diffuse into intracellular compartments extensively.

Metabolism:
Lanadelumab is catabolized via nonspecific proteolytic pathways. Like other monoclonal antibodies, it undergoes cellular uptake via endocytosis and degradation within lysosomes to small peptides and amino acids, which are further recycled or eliminated. It is not metabolized by cytochrome P450 enzymes, minimizing drug-drug metabolic interactions. The elimination pathways are consistent with its protein structure and are not influenced by hepatic or renal impairment.

Elimination:
The elimination half-life of lanadelumab is approximately 14 to 21 days, supporting its biweekly dosing regimen. Elimination follows nonspecific protein catabolism rather than renal or hepatic clearance. Due to its size and structure, renal filtration is negligible. The long half-life enables sustained kallikrein inhibition with decreased frequency of administration. Clearance rates do not significantly vary between adult and pediatric patients aged 2 years and above, indicating stable elimination irrespective of age within the approved patient populations.

Dosage Forms

Available Dosage Forms:
Lanadelumab is available exclusively as a subcutaneous injection in two major presentations:
- Single-dose prefilled syringes containing 150 mg/mL; available as both 1 mL (150 mg) and 2 mL (300 mg) doses.
- Single-dose glass vials containing 300 mg/2 mL (150 mg/mL) concentration.

Dosages for Adults and Adolescents:
- For patients aged 12 years and older, the recommended initial dosing is 300 mg administered subcutaneously every two weeks.
- After achieving control of hereditary angioedema symptoms, a maintenance dosing schedule of 300 mg every four weeks may be considered to reduce injection frequency.

Specific Patient Populations:
- Pediatric patients aged 6 to less than 12 years receive an initial dose of 150 mg subcutaneously every two weeks, with potential extension to every four weeks as maintenance upon symptom control.
- Pediatric patients aged 2 to less than 6 years are dosed at 150 mg subcutaneously every four weeks; self-injection is generally not recommended in children younger than 12 years.
- Dose adjustments are primarily based on age and clinical response rather than weight or renal/hepatic function due to monoclonal antibody pharmacology.

Clinical Guidelines:
- Patients should be trained by healthcare providers on proper injection technique prior to self-administration.
- The medication should be allowed to reach room temperature for 15 minutes before injection and not be shaken to maintain antibody integrity.
- Single-dose vials and syringes are intended for single use only to avoid contamination risks.
- Injection sites should be rotated to reduce local site reactions.

Mechanism Of Action

Lanadelumab is a fully human monoclonal antibody specifically designed to inhibit plasma kallikrein, a serine protease critically involved in the pathogenesis of hereditary angioedema (HAE). By selectively binding to active plasma kallikrein, lanadelumab prevents the cleavage of high molecular weight kininogen, thereby reducing the generation of bradykinin, the primary mediator of angioedema attacks.

At the molecular level, lanadelumab exhibits high affinity and specificity for plasma kallikrein's active site, blocking its enzymatic activity without affecting prekallikrein or other proteases. This inhibitory action disrupts the kallikrein-kinin system cascade, markedly lowering bradykinin levels in plasma. Bradykinin is responsible for increasing vascular permeability leading to localized swelling; its suppression effectively reduces both the frequency and severity of HAE attacks.

Clinically, the reduction of bradykinin by lanadelumab translates to prevention of recurrent swelling episodes characteristic of HAE, including those affecting extremities, face, gastrointestinal tract, and airway tissues. Unlike acute treatment agents, lanadelumab's prolonged half-life allows prophylactic use, providing sustained kallikrein inhibition.

Comparatively, other agents targeting the kallikrein-kinin system may be small molecule inhibitors or plasma-derived C1 esterase inhibitors; lanadelumab is notable for its monoclonal antibody structure offering targeted, long-lasting therapy with a favorable dosing schedule. Published clinical trials validate its efficacy and safety, demonstrating significant reductions in attack rates and improved quality of life in patients with HAE.

Pharmacological Actions

Selective inhibition of plasma kallikrein, a key enzyme in the kallikrein-kinin system.
Reduction of bradykinin production, the main mediator of hereditary angioedema swelling episodes.
Prophylactic prevention of hereditary angioedema attacks by maintaining sustained kallikrein blockade.
Monoclonal antibody mechanism with high target specificity and minimal off-target effects.
Prolonged half-life allowing biweekly to monthly subcutaneous administration for patient convenience.
Non-competitive inhibition of plasma kallikrein’s enzymatic activity.
Reduction of vascular permeability and inflammation via decreased bradykinin-mediated signaling.
Minimal metabolism by hepatic enzymes, lowering risk of drug-drug interactions.
Negligible intracellular penetration, focusing action on circulating kallikrein.
Immunomodulating effects limited to kallikrein inhibition without broad immune suppression.
Rapid onset of action post initial dosing with peak plasma levels within two weeks.
Applicable in both adult and pediatric populations aged 2 years and older with dosing flexibility.

Therapeutic Or Clinical Uses

Prophylactic treatment to prevent hereditary angioedema (HAE) attacks in adults and children ≥2 years.
Reduction in frequency and severity of HAE episodes characterized by subcutaneous or submucosal swelling.
Management of HAE-associated swelling affecting face, extremities, gastrointestinal organs, and airways.
Therapy for patients with congenital C1 esterase inhibitor deficiency-related angioedema conditions.
Prevention of life-threatening airway swelling in hereditary angioedema patients.
Suitable for maintenance therapy in pediatric patients to improve quality of life.
Use in patients requiring long-term prophylaxis against HAE attacks.
Management option for patients who are unresponsive or intolerant to plasma-derived C1 esterase inhibitors.
Alternative prophylactic therapy for patients preferring subcutaneous administration over intravenous medications.
Part of multimodal HAE management strategies incorporating both prophylaxis and acute treatment.
Indicated for reducing healthcare utilization and emergency interventions triggered by HAE attacks.
Supportive treatment to reduce psychological burden and improve daily functioning in HAE patients.
Facilitates decreased dependence on rescue medications such as icatibant or ecallantide.
Clinically proven in randomized controlled trials (HELP, HELP OLE, SPRING studies).

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling, and bruising may occur frequently.
Upper respiratory tract infections such as nasopharyngitis and sinusitis.
Headache of varying intensity reported in clinical trials.
Rash and other mild dermatologic manifestations.
Dizziness or lightheadedness during or following administration in some patients.
Gastrointestinal symptoms including diarrhea.
Muscle aches or myalgia may be reported transiently.
Rare but serious hypersensitivity reactions including anaphylaxis.
Potential for allergic reactions manifesting as hives, wheezing, chest tightness, or rapid heartbeat.
Fatigue and general malaise observed in a minority of patients.
No significant hepatotoxicity or nephrotoxicity documented.
No increased risk of immunosuppression-related infections reported.
Local injection site bleeding or bruising in patients on concomitant anticoagulants.
Post-marketing surveillance to monitor for rare adverse events ongoing.
Side effects generally mild to moderate and manageable with supportive care.

Precautions

Avoid use in individuals with known hypersensitivity to lanadelumab or any inactive ingredients.
Not approved for use in children under 2 years of age.
Patients should inform healthcare providers about concurrent medications to prevent possible interactions.
Use caution in patients with a history of severe allergic reactions; monitor for anaphylaxis.
Self-injection training is essential; improper administration may lead to injection site complications.
Maintain proper storage conditions to preserve drug integrity (refrigerated, do not freeze or shake).
Pregnant or breastfeeding women should consult healthcare providers due to insufficient safety data.
May interfere with certain diagnostic tests; inform all medical personnel about use of lanadelumab.
Not a treatment for acute HAE attacks; patients must have access to appropriate rescue medications.
Dose adjustments not routinely required based on renal or hepatic function due to protein catabolism elimination.
Patients should be monitored periodically for efficacy and adverse effects, especially during dose interval changes.
Children aged 2-12 are generally not recommended for self-administration; caregiver involvement advised.
Avoid abrupt discontinuation without medical consultation to prevent rebound HAE attacks.
Ensure patient adherence to dosing intervals to maintain effective kallikrein inhibition.
Educate patients about signs of hypersensitivity and when to seek immediate medical care.

Warnings

Risk of serious allergic reactions including anaphylaxis; immediate medical attention required upon symptom onset.
Not a substitute for emergency treatment of acute HAE attacks; carry rescue medications at all times.
Monitor injection sites for signs of infection or severe local reactions.
Potential immunogenicity with development of anti-drug antibodies, although clinical significance appears low.
Use during pregnancy only if potential benefits justify potential risk to the fetus; insufficient human data.
Safety in breastfeeding has not been established; caution advised.
Avoid exposure to extreme temperatures; improper storage can degrade drug efficacy and safety.
Do not shake solution to prevent protein destabilization which could reduce effectiveness or increase adverse effects.
Report any unusual bleeding, bruising, or symptoms suggesting coagulation abnormalities to healthcare provider.
Use with caution in patients with concurrent immunological disorders; clinical data limited.
Should not be administered intravenously; risk of adverse reactions associated with injection route.
Discontinue and seek medical attention if signs of hypersensitivity or severe skin reactions develop.
Patients with poor injection technique or cognitive impairment may require caregiver assistance.
Long-term safety data continue to be collected; new warnings may emerge post-marketing.
No evidence of increased malignancy risk but remain vigilant due to chronic immunomodulation.

Contraindication

Known hypersensitivity or allergic reaction to lanadelumab or any component of the formulation.
History of anaphylaxis or severe hypersensitivity to other monoclonal antibody therapies may warrant caution.
Not indicated for treatment of acute hereditary angioedema attacks; contraindicated as monotherapy in acute setting.
Use is contraindicated in children under 2 years old due to lack of safety and efficacy data.
Do not use if the product is visibly discolored or contains particulate matter; contamination risk.
Contraindicated if patient has had an adverse reaction to previous lanadelumab doses without medical supervision.
Not recommended in patients with active severe infections until infection is controlled.
Contraindicated in patients allergic to inactive ingredients such as polysorbate 80, histidine, or citric acid monohydrate.
Avoid in patients with known bleeding disorders unless benefits outweigh risks and under careful monitoring.
Contraindicated in settings requiring immediate reduction of kallikrein activity; onset of action is delayed.
Use with caution in patients with immunodeficiencies due to potential unknown immune consequences.
Injection containing single-use vials or prefilled syringes cannot be reused; contravening this may cause contraindications related to contamination.

Drug Interactions

Minimal drug-drug interactions expected due to catabolic metabolism not involving cytochrome P450 enzymes.
No significant interactions reported with commonly prescribed concomitant medications including vitamins and herbal supplements.
No known interference with anticoagulants but monitor injection sites for bleeding or bruising.
Potential interference with laboratory tests measuring kallikrein or related enzymatic activities; inform lab personnel.
No documented interactions with other hereditary angioedema treatments when used for acute attacks.
Concomitant use with immunosuppressants should be monitored for additive immunomodulatory effects.
Herbal supplements such as St John’s Wort are unlikely to affect lanadelumab pharmacokinetics.
Drug interaction data in pediatric populations is limited; clinical monitoring recommended.
No known effect on efficacy of hormonal contraceptives or other common medications.
Lanadelumab may affect certain biochemical assays; clinical correlation necessary if unexpected results occur.
No major contraindications for combination with vaccines but evaluate patient immune status prior to live vaccines.
No known adverse interactions with over-the-counter medications like analgesics or antihistamines.
No significant interactions expected with renal or hepatic metabolism-dependent drugs.
Drug interaction risk low due to monoclonal antibody structure and proteolytic clearance.
Ongoing pharmacovigilance for potential rare or newly identified interactions in larger populations.

Preparations Of The Drug

Prefilled syringe: 150 mg/mL concentration, available in 1 mL (150 mg) and 2 mL (300 mg) volumes.
Single-dose glass vial: 300 mg/2 mL (150 mg/mL) for subcutaneous injection after reconstitution/preparation.
Formulated with inactive ingredients such as citric acid monohydrate, histidine, sodium chloride, polysorbate 80, and sodium phosphate dibasic dihydrate for stability.
Packaged individually to ensure single-use to reduce contamination risk.
Supplied refrigerated and requires storage at 2°C to 8°C (36°F to 46°F); do not freeze.
Vials and syringes should be protected from light; keep in original carton until use.
Shaking is prohibited to avoid protein denaturation and loss of efficacy.
Prefilled syringes are ready-to-use and do not require reconstitution or dilution.
Single-dose vial requires preparation immediately prior to administration, with a use window of 2 hours post-preparation.
Packaging includes sterile, disposable needles and instructions for safe handling and disposal.
Available commercially under the brand name Takhzyro, manufactured by Takeda Pharmaceuticals U.S.A., Inc.
Storage containers comply with safety and sharps disposal regulations.
Each preparation is factory sealed to maintain sterility and drug stability.
Supplied with patient instruction leaflets detailing administration and storage recommendations.
Preparations are not transferable between patients; single-patient use only.